Javascript must be enabled to continue!
Data from MDM2 Controls the Timely Expression of Cyclin A to Regulate the Cell Cycle
View through CrossRef
<div>Abstract<p>Overexpression of MDM2 has been related to oncogenesis. In this communication, we present evidence to show that MDM2 controls the cell cycle–dependent expression of cyclin A by using a pathway that ensures its timely expression. MDM2 does not inhibit cyclin D or E expression. Silencing of endogenous MDM2 expression elevates cyclin A expression. The p53-binding domain of MDM2 harbors a SWIB region homologous to a conserved domain of a chromosome remodeling factor BRG1-associated protein. The SWIB domain of MDM2 inhibits cyclin A expression in a p53- and BRG1-dependent fashion, suggesting that MDM2 interferes with p53 binding of the BRG1 complex freeing it to repress cyclin A expression. Silencing of cyclin-dependent kinase (cdk) inhibitor p16 prevents MDM2-mediated inhibition of cyclin A expression, implicating its role in the process. MDM2-mediated repression of cyclin A expression induces G<sub>1</sub>-S arrest, which can be rescued by ectopic expression of cyclin A. Cancer cells lacking p53, p16, or BRG1 escape MDM2-mediated repression of cyclin A expression and growth arrest. Our data propose a novel mechanism by which MDM2 controls the cell cycle in normal cells and how cancer cells may escape this important safety barrier. (Mol Cancer Res 2009;7(8):1253–67)</p></div>
American Association for Cancer Research (AACR)
Title: Data from MDM2 Controls the Timely Expression of Cyclin A to Regulate the Cell Cycle
Description:
<div>Abstract<p>Overexpression of MDM2 has been related to oncogenesis.
In this communication, we present evidence to show that MDM2 controls the cell cycle–dependent expression of cyclin A by using a pathway that ensures its timely expression.
MDM2 does not inhibit cyclin D or E expression.
Silencing of endogenous MDM2 expression elevates cyclin A expression.
The p53-binding domain of MDM2 harbors a SWIB region homologous to a conserved domain of a chromosome remodeling factor BRG1-associated protein.
The SWIB domain of MDM2 inhibits cyclin A expression in a p53- and BRG1-dependent fashion, suggesting that MDM2 interferes with p53 binding of the BRG1 complex freeing it to repress cyclin A expression.
Silencing of cyclin-dependent kinase (cdk) inhibitor p16 prevents MDM2-mediated inhibition of cyclin A expression, implicating its role in the process.
MDM2-mediated repression of cyclin A expression induces G<sub>1</sub>-S arrest, which can be rescued by ectopic expression of cyclin A.
Cancer cells lacking p53, p16, or BRG1 escape MDM2-mediated repression of cyclin A expression and growth arrest.
Our data propose a novel mechanism by which MDM2 controls the cell cycle in normal cells and how cancer cells may escape this important safety barrier.
(Mol Cancer Res 2009;7(8):1253–67)</p></div>.
Related Results
Data from MDM2 Controls the Timely Expression of Cyclin A to Regulate the Cell Cycle
Data from MDM2 Controls the Timely Expression of Cyclin A to Regulate the Cell Cycle
<div>Abstract<p>Overexpression of MDM2 has been related to oncogenesis. In this communication, we present evidence to show that MDM2 controls the cell cycle–dependent e...
Abstract 1234: Impact of cancer-associated mutations on MDM2 function
Abstract 1234: Impact of cancer-associated mutations on MDM2 function
Abstract
MDM2 is an E3 ubiquitin ligase that functions as a negative regulator of the tumor suppressor p53. MDM2 can promote the ubiquitination and proteasomal degra...
Ribosomal Protein S4 X-Linked as a Novel Modulator of MDM2 Stability by Suppressing MDM2 Auto-Ubiquitination and SCF Complex-Mediated Ubiquitination
Ribosomal Protein S4 X-Linked as a Novel Modulator of MDM2 Stability by Suppressing MDM2 Auto-Ubiquitination and SCF Complex-Mediated Ubiquitination
Mouse double minute 2 (MDM2) is an oncoprotein that is frequently overexpressed in tumors and enhances cellular transformation. Owing to the important role of MDM2 in modulating p5...
Inhibition of MDM2 via Nutlin-3A: A Potential Therapeutic Approach for Pleural Mesotheliomas with MDM2-Induced Inactivation of Wild-Type P53
Inhibition of MDM2 via Nutlin-3A: A Potential Therapeutic Approach for Pleural Mesotheliomas with MDM2-Induced Inactivation of Wild-Type P53
Previously, our group demonstrated that nuclear expression of E3 ubiquitin ligase (MDM2) in malignant pleural mesothelioma (MPM) is significantly associated with decreased overall ...
Complex Collision Tumors: A Systematic Review
Complex Collision Tumors: A Systematic Review
Abstract
Introduction: A collision tumor consists of two distinct neoplastic components located within the same organ, separated by stromal tissue, without histological intermixing...
Abstract 1792: MDM2 promoter variants and mRNA expression in irradiated lymphocytes.
Abstract 1792: MDM2 promoter variants and mRNA expression in irradiated lymphocytes.
Abstract
Background. The ubiquitin ligase protein MDM2 plays an important role in cellular processes like growth arrest, senescence and apoptosis, and one of its mai...
Estradiol Stabilizes p53 Protein in Breast Cancer Cell Line, MCF–7
Estradiol Stabilizes p53 Protein in Breast Cancer Cell Line, MCF–7
Overexpression of the oncoprotein MDM2, an important regulator of the p53 tumor suppressor protein, is often observed in breast cancer tissues and cell lines, particularly in those...
Expression of the retinoblastoma protein in low-grade B-cell lymphoma: relationship to cyclin D1
Expression of the retinoblastoma protein in low-grade B-cell lymphoma: relationship to cyclin D1
Abstract
The product of the retinoblastoma tumor-suppressor gene (pRB), a nuclear phosphoprotein that regulates transcription factors such as E2F, is involved in cel...

